$CAH

Mason Stephen M sold $8.3M of CAH

Mason Stephen M (CEO, GMPD Segment) sold 35,000 shares of CARDINAL HEALTH INC (CAH) at an average of $236.40 ($234.59–$237.26, $8.27M total) across 4 trades on 2026-08-18.

Original reporting
SEC EDGAR · Mason Stephen M
Published Aug 20, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 11:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAH
Bearish
medium confidence
Mentioned
$CAH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAHBearishLow
01

Why it matters

The $8.3M sale is the first public disclosure of this insider activity, providing new data for valuation models.

02

Market read

The insider sale adds fresh negative sentiment for CAH and may trigger short‑term price adjustments.

03

What to watch

CEO may have tax or liquidity reasons; the remaining stake remains large.

Relevance 6/10Novelty 7/10Timing: filing date 2026-08-20

Background

Form 4 filings disclose insider transactions; a CEO sale is closely watched by traders.

Company-level read

Ticker impact

$CAHBearishMedium confidence
Context

CEO Mason Stephen M sold 35,000 shares for $8.27M, reducing his stake to 18,061 shares.

Expected impact

downward pressure in the near term

Evidence & confidence

A $8.3M open‑market sale by the chief executive is material and suggests potential concerns, but the remaining stake is still sizable.

Market effects

Minimal impact on the healthcare distribution sector beyond CAH.

U.S. market only; no broader regional effect.

Limited to investors tracking CAH.

Counterpoint

The sale could be a routine diversification rather than a bearish signal.

Key entities

  • Cardinal Health Inc.

    U.S. healthcare services and products distributor.

  • Mason Stephen M

    CEO of Cardinal Health's GMPD segment.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAHMed

How CVS Deal Extension At Cardinal Health (CAH) Has Changed Its Investment Story

Cardinal Health (CAH) extended its pharmaceutical distribution agreement with CVS Health until 2032, reaffirming its fiscal 2027 non-GAAP EPS growth guidance of 13% to 15%. The extension secures a key partner, supporting Cardinal's strategy to shift toward higher-margin services. Analysts expect revenue of $297.6 billion and earnings of $3.0 billion by 2029. The company's upcoming Q1 results on November 5 will provide further insights.

$CAHHigh

Why is Cardinal Health stock rallying today?

Cardinal Health (CAH) stock rose 3.8% after extending its pharmaceutical distribution agreement with CVS Health (CVS) until 2032, removing investor uncertainty. The company reaffirmed its FY2027 EPS guidance of $12.40-$12.60. Today is the ex-dividend date for its quarterly dividend of $0.516 per share. The stock reached $235.95 intraday, with broader market gains providing a supportive backdrop.

$MCKMed

McKesson (MCK) and Cardinal Health Extend CVS Health Distributio

McKesson (MCK) and Cardinal Health renewed their pharmaceutical distribution agreements with CVS Health, extending contracts through June 2032. Both companies reaffirmed their fiscal 2027 earnings guidance. McKesson's stock is trading at $890.28, 6.8% above its GF Value of $833.49, with a GF Score of 86/100. Insider sales totaled $28.3 million over the past year, while 15 premium gurus hold MCK with a net positive addition.

$CAHMed

Why Is Cardinal Health and McKesson Stock Trading Higher Today - CVS Health (NYSE:CVS), McKesson (NYSE:MC

Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.